Enforcement Report - Week of May 29, 2024
Enforcement Report - Week of February 21, 2024
Gland Pharma`s Generic Vasopressin Receives Approval in the U.S.
Enforcement Report - Week of January 24, 2024
Cipla`s Generic Vasopressin Receives Approval in the U.S.
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®. Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20 Units per 1 mL Single Dose Vial.
Enforcement Report - Week of May 31, 2023
FDA Confirms Paragraph IV Patent Litigation for Vasopressin Injection
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s decision that Eagle’s vasopressin product does not infringe on any of the patents asserted by Par Pharmaceutical, Inc. (“Par”).